Literature DB >> 16878132

Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy.

Mani S Mahadevan1, Ramesh S Yadava, Qing Yu, Sadguna Balijepalli, Carla D Frenzel-McCardell, T David Bourne, Lawrence H Phillips.   

Abstract

Myotonic dystrophy (DM1), the most common muscular dystrophy in adults, is caused by an expanded (CTG)n tract in the 3' UTR of the gene encoding myotonic dystrophy protein kinase (DMPK), which results in nuclear entrapment of the 'toxic' mutant RNA and interacting RNA-binding proteins (such as MBNL1) in ribonuclear inclusions. It is unclear if therapy aimed at eliminating the toxin would be beneficial. To address this, we generated transgenic mice expressing the DMPK 3' UTR as part of an inducible RNA transcript encoding green fluorescent protein (GFP). We were surprised to find that mice overexpressing a normal DMPK 3' UTR mRNA reproduced cardinal features of myotonic dystrophy, including myotonia, cardiac conduction abnormalities, histopathology and RNA splicing defects in the absence of detectable nuclear inclusions. However, we observed increased levels of CUG-binding protein (CUG-BP1) in skeletal muscle, as seen in individuals with DM1. Notably, these effects were reversible in both mature skeletal and cardiac muscles by silencing transgene expression. These results represent the first in vivo proof of principle for a therapeutic strategy for treatment of myotonic dystrophy by ablating or silencing expression of the toxic RNA molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16878132      PMCID: PMC2909745          DOI: 10.1038/ng1857

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  30 in total

1.  Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice.

Authors:  G Jansen; P J Groenen; D Bächner; P H Jap; M Coerwinkel; F Oerlemans; W van den Broek; B Gohlsch; D Pette; J J Plomp; P C Molenaar; M G Nederhoff; C J van Echteld; M Dekker; A Berns; H Hameister; B Wieringa
Journal:  Nat Genet       Date:  1996-07       Impact factor: 38.330

2.  Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.

Authors:  Marc-André Langlois; Nan Sook Lee; John J Rossi; Jack Puymirat
Journal:  Mol Ther       Date:  2003-05       Impact factor: 11.454

3.  Structure and genomic sequence of the myotonic dystrophy (DM kinase) gene.

Authors:  M S Mahadevan; C Amemiya; G Jansen; L Sabourin; S Baird; C E Neville; N Wormskamp; B Segers; M Batzer; J Lamerdin
Journal:  Hum Mol Genet       Date:  1993-03       Impact factor: 6.150

4.  Muscleblind proteins regulate alternative splicing.

Authors:  Thai H Ho; Nicolas Charlet-B; Michael G Poulos; Gopal Singh; Maurice S Swanson; Thomas A Cooper
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

5.  Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.

Authors:  M Mahadevan; C Tsilfidis; L Sabourin; G Shutler; C Amemiya; G Jansen; C Neville; M Narang; J Barceló; K O'Hoy
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

6.  Transgenic overexpression of human DMPK accumulates into hypertrophic cardiomyopathy, myotonic myopathy and hypotension traits of myotonic dystrophy.

Authors:  D Fearghas O'Cochlain; Carmen Perez-Terzic; Santiago Reyes; Garvan C Kane; Atta Behfar; Denice M Hodgson; Jeffrey A Strommen; Xiao-Ke Liu; Walther van den Broek; Derick G Wansink; Bé Wieringa; Andre Terzic
Journal:  Hum Mol Genet       Date:  2004-08-18       Impact factor: 6.150

7.  Inhibition of myogenesis in transgenic mice expressing the human DMPK 3'-UTR.

Authors:  Christopher J Storbeck; Suzana Drmanic; Kate Daniel; James D Waring; Frank R Jirik; David J Parry; Nazim Ahmed; Luc A Sabourin; Joh-E Ikeda; Robert G Korneluk
Journal:  Hum Mol Genet       Date:  2004-01-20       Impact factor: 6.150

8.  Overexpression of CUG triplet repeat-binding protein, CUGBP1, in mice inhibits myogenesis.

Authors:  Nikolai A Timchenko; Roma Patel; Polina Iakova; Zong-Jin Cai; Ling Quan; Lubov T Timchenko
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

9.  Correlation between cardiac involvement and CTG trinucleotide repeat length in myotonic dystrophy.

Authors:  P Melacini; C Villanova; E Menegazzo; G Novelli; G Danieli; G Rizzoli; G Fasoli; C Angelini; G Buja; M Miorelli
Journal:  J Am Coll Cardiol       Date:  1995-01       Impact factor: 24.094

10.  Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues.

Authors:  K L Taneja; M McCurrach; M Schalling; D Housman; R H Singer
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  97 in total

Review 1.  Neurodegeneration the RNA way.

Authors:  Abigail J Renoux; Peter K Todd
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Role of noncoding RNAs in trinucleotide repeat neurodegenerative disorders.

Authors:  Huiping Tan; Zihui Xu; Peng Jin
Journal:  Exp Neurol       Date:  2012-01-27       Impact factor: 5.330

Review 3.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

4.  Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cells.

Authors:  Claudia Huichalaf; Keiko Sakai; Bingwen Jin; Karlie Jones; Guo-Li Wang; Benedikt Schoser; Christiane Schneider-Gold; Partha Sarkar; Olivia M Pereira-Smith; Nikolai Timchenko; Lubov Timchenko
Journal:  FASEB J       Date:  2010-05-17       Impact factor: 5.191

5.  High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany.

Authors:  T Suominen; B Schoser; O Raheem; S Auvinen; M Walter; R Krahe; H Lochmüller; W Kress; B Udd
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

6.  Dystrophia myotonia: why focus on foci?

Authors:  R P Junghans
Journal:  Eur J Hum Genet       Date:  2009-01-28       Impact factor: 4.246

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 8.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

Review 9.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

10.  Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.

Authors:  Guey-Shin Wang; Debra L Kearney; Mariella De Biasi; George Taffet; Thomas A Cooper
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.